vs
Side-by-side financial comparison of Sanofi (SNY) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of th...
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $829.5K | ||
| Q3 24 | — | $829.5K | ||
| Q3 23 | — | $939.6K | ||
| Q3 22 | — | $1.2M | ||
| Q3 21 | — | $1.0M |
| Q3 25 | — | $-802.6K | ||
| Q3 24 | — | $-802.6K | ||
| Q3 23 | — | $-9.7M | ||
| Q3 22 | — | $-1.5M | ||
| Q3 21 | — | $-3.1M |
| Q3 25 | — | 16.2% | ||
| Q3 24 | — | 16.2% | ||
| Q3 23 | — | 30.7% | ||
| Q3 22 | — | 7.4% | ||
| Q3 21 | — | 31.5% |
| Q3 25 | — | -76.9% | ||
| Q3 24 | — | -76.9% | ||
| Q3 23 | — | -995.0% | ||
| Q3 22 | — | -95.2% | ||
| Q3 21 | — | -281.4% |
| Q3 25 | — | -96.8% | ||
| Q3 24 | — | -96.8% | ||
| Q3 23 | — | -1032.0% | ||
| Q3 22 | — | -123.7% | ||
| Q3 21 | — | -300.9% |
| Q3 25 | — | — | ||
| Q3 24 | — | $-0.25 | ||
| Q3 23 | — | $-19.34 | ||
| Q3 22 | — | $-14.61 | ||
| Q3 21 | — | $-3.98 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
